Tabel 4.
Respiratory characteristics before Enoximone (admission ICU) – after 24 h – after 48 h.
| Standard care | PATIENT | DATE | RESP. SUPPORT | FiO2 | RESP. RATE |
TIDAL VOLUME |
MINUTE VOLUME | PEAK/PEEP PRESSURE | RESP. VALUES | TIME |
|---|---|---|---|---|---|---|---|---|---|---|
| A* | 04-04-2020 | PCV | 80% | 22 | 475 | 5,1 | 22/14 | - | 18.24 h | |
| 05-04-2020 | PCV | 40% | 20 | 413 | 4,9 | 31/09 | - | 18.24 h | ||
| 06-04-2020 | Pr Supp | 40% | 21 | 484 | 6,1 | 14/10 | - | 18.24 h | ||
| B* | 07-04-2020 | PCV | 55% | 20 | 422 | 6,2 | 23/14 | - | 18.18 h | |
| 08-04-2020 | Pr Supp | 40% | 21 | 492 | 10,0 | 16/08 | - | 18.18 h | ||
| 09-04-2020 | Pr Supp | 55% | 15 | 433 | 7,6 | 15/10 | - | 18.18 h | ||
| C* | 08-04-2020 | PCV | 55% | 20 | 458 | 6,6 | 23/14 | - | 12.35 h | |
| 09-04-2020 | PCV | 50% | 24 | 435 | 6,4 | 25/10 | - | 12.35 h | ||
| 10-04-2020 | PCV | 41% | 24 | 430 | 6,0 | 25/11 | - | 12.35 h | ||
| Add-on enoximone | 1# | 17-05-2020 | Optiflow™ | 45% | 16 | – | – | – | 45%/60 L | 16.24 h |
| 18-05-2020 | none | – | 15 | – | – | – | 6 L O2 (nasal probe) |
16.24 h | ||
| 19-05-2020 | none | – | 16 | – | – | – | 2 L O2 (nasal probe) |
16.24 h | ||
| 2# | 24-05-2020 | Optiflow™ | 65% | – | – | – | – | 65%/50 L | 11.26 h | |
| 25-05-2020 | Optiflow™ | 60% | – | – | – | – | 60%/60 L | 11.26 h | ||
| 26-05-2020 | none | – | – | – | – | – | 6 L O2 (nasal probe) |
11.26 h | ||
| 3# | 24-05-2020 | Optiflow™ | 100% | 24 | – | – | – | 100%/60 L | 22.27 h | |
| 25-05-2020 | Optiflow™ | 55% | 12 | – | – | – | 55%/50 L | 22.27 h | ||
| 26-05-2020 | Optiflow™ | 60% | 13 | – | – | – | 60%/60 L | 22.27 h | ||
| 4# | 08-07-2020 | Optiflow™ | 55% | – | – | – | – | 55%/60 L | 12.51 h | |
| 09-07-2020 | Optiflow™ | 50% | – | – | – | – | 50%/55 L | 12.51 h | ||
| 10-07-2020 | Optiflow™ | 50% | – | – | – | – | 50%/50 L | 12.51 h |
*
= conventional treatment only (pts A-C);
#
= add on-enoximone (pts number 1-4).